Precision Epigenomic, Inc. presents a bioinformatics study demonstrating that Sentinel-10™ can detect 20 different cancer types and clinical data on breast cancer at the Annual Association of Molecular Pathology meeting 2023 in Phoenix

Precision Epigenomics, Inc. presents a pilot study of the performance of Sentinel-10™ for hepatocellular carcinoma at the Digestive Disease Week Annual Meeting 2023 in Chicago

Precision Epigenomics, Inc. presents results of the performance of the Sentinel-MPE™ test at the annual American Thoracic Society meeting 2023 in Washington, DC 


Precision Epigenomics, Inc. and Arizona State University collaborators are awarded a training grant by National Human Genome Research Institute to train students in bioinformatics through the Training in Genomics Research program




Precision Epigenomics, Inc. and University of Arizona collaborators awarded a pilot project to develop a new molecular test for indeterminate melanoma lesions




The National Cancer Institute awards $397,000 grant to Precision Epigenomics

February 1, 2022 – The National Cancer Institute awards a $397,000 NIH SBIR Phase I project to Precision Epigenomics titled: Lung Cancer, DNA Methylation, and Liquid Biopsy.

Precision Epigenomics is highlighted at University of Arizona Research Day

April 2021 – Precision Epigenomics Inc was selected to present their findings regarding the development of a liquid biopsy assay for non-small cell lung to the leadership and faculty of the University of Arizona.

Precision Epigenomics, Inc. selected into Bizlaunch Program

August 2020 – Precision Epigenomics was chosen by the Town of Sahuarita for sponsorship in the Bizlaunch program run by the University of Arizona Center for Innovation (UACI). The Bizlaunch program is funded by the Town of Sahuarita and Freeport-McMoRan. Precision Epigenomics was chosen because of our connection to the town, the benefit of our technology to the community and globe, and innovation.